Prostate Cancer: Understanding Active Surveillance

What is Active Surveillance for Prostate Cancer?

Prostate cancer is a significant health concern for many men, but not all cases require immediate, aggressive treatment. For slow-growing prostate cancers, a strategy known as active surveillance is often recommended. This approach involves closely monitoring the cancer with regular medical tests rather than starting treatment right away. The goal is to avoid or delay the potential side effects of treatment while ensuring the cancer is managed effectively. In India, as globally, understanding this option is crucial for informed decision-making.

Why Choose Active Surveillance?

Most prostate cancers tend to progress slowly, and the survival rate for those diagnosed is very high, often exceeding 98%. Treatment for prostate cancer, while potentially life-saving, can lead to side effects such as urinary incontinence or sexual dysfunction. Active surveillance offers a way to potentially delay or reduce these side effects, particularly for men with low-risk prostate cancer, without significantly compromising their chances of survival. This approach is increasingly being adopted by doctors worldwide, including in India, reflecting a growing understanding of the nuances of prostate cancer management.

What Does Active Surveillance Entail?

Active surveillance, also referred to as expectant management or deferred therapy, involves a healthcare team monitoring your prostate cancer through a series of tests to observe any changes over time. No specific treatment is administered during this phase. Your doctor might suggest active surveillance if your cancer is:

• Diagnosed as low-grade.
• Small in size.
• Confined to one side of the prostate.
• Not showing signs of rapid growth.

The Gleason score is a key factor in classifying prostate cancer cells and assessing their aggressiveness. A lower Gleason score typically indicates a slower-growing cancer, making it a candidate for active surveillance. However, it's important to note that younger men and those in excellent overall health might be less likely to be offered active surveillance, as there's a consideration for potential long-term concerns. This is a decision made in consultation with your doctor, taking into account your individual health profile and risk factors.

Active Surveillance vs. Watchful Waiting

A similar concept that doctors sometimes recommend is watchful waiting. The key difference lies in the trigger for treatment. Watchful waiting involves delaying treatment until symptoms develop, with the aim of managing those symptoms rather than curing the cancer. This approach is often recommended for older men or those with other serious health conditions where the benefits of active treatment might be limited. Active surveillance, on the other hand, is a more proactive monitoring strategy for cancer that is already detected, even without immediate symptoms.

The Monitoring Process

The monitoring process under active surveillance typically involves a combination of tests, which may include:

1. Prostate-Specific Antigen (PSA) Tests: Regular blood tests to measure PSA levels. Elevated PSA can indicate cancer growth. PSA levels under 10 nanograms per milliliter (ng/mL) are often associated with low-risk prostate cancer suitable for surveillance.
2. Digital Rectal Exams (DRE): A physical examination by the doctor to feel the prostate for any abnormalities.
3. Prostate Biopsies: Repeat biopsies may be performed periodically to check for any changes in the cancer's grade or aggressiveness.
4. Imaging Tests: Techniques like MRI (Magnetic Resonance Imaging) can provide detailed images of the prostate to monitor for any structural changes or tumor growth.

The frequency of these tests is determined by your doctor based on your specific condition and risk factors. In a 2023 study, researchers found a significant increase in the number of doctors recommending active surveillance for low-risk prostate cancer, highlighting its growing acceptance.

When to Switch to Active Treatment

The decision to switch from active surveillance to active treatment is based on specific criteria. According to 2023 research and expert consensus, the switch may be decided based on:

• A significant increase in PSA levels.
• Changes in the DRE findings.
• New findings from repeat biopsies indicating a more aggressive cancer.
• Patient preference or new concerns.

Studies have shown excellent outcomes for men on active surveillance. Research from 2021 examining long-term data found that for men with grade 1 cancer, the probability of being treatment-free at 5, 10, and 15 years was very high. Importantly, the risk of cancer spreading to distant parts of the body or causing death from prostate cancer remained very low in these cases.

Potential Side Effects of Treatment

It is crucial to understand the potential side effects associated with active cancer treatments, such as surgery or radiation therapy. These can include:

• Urinary incontinence (inability to control urination).
• Sexual dysfunction, including erectile dysfunction.
• Bowel problems.
• Fatigue.

By opting for active surveillance when appropriate, men can potentially avoid or postpone these side effects, thereby maintaining a better quality of life.

When to Consult a Doctor

If you are a man over 50, or if you have a family history of prostate cancer, it is essential to discuss regular screening with your doctor. If you have been diagnosed with prostate cancer, especially a low-risk form, have an open conversation about whether active surveillance is a suitable option for you. Early detection and informed choices are key to managing prostate cancer effectively. Don't hesitate to seek medical advice if you have any concerns or questions regarding your prostate health.